You are here

HUMAN COLLAGENASE IV AND ITS INHIBITORS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16420
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1991
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
19 Firstfield Road
Gaithersburg, MD 20878
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Bird, Robert E
 Principal Investigator
 (301) 590-2600
Business Contact
 1 R43 CA54662-01
Phone: () -
Research Institution
N/A
Abstract

THE DEGRADATION OF THE COLLAGEN TYPE IV NETWORK IN BASEMENT MEMBRANES IS A CRITICAL EVENT IN MANY NORMAL AND PATHOLOGICAL CONDITIONS INCLUDING TISSUE REMODELLING, WOUND HEALING, TUMOR CELL METASTASIS, AND ANGIOGENESIS. THE 72 KD TYPE IV COLLAGENASE IS A NEUTRAL METALLOPROTEASE CAPABLE OF DEGRADING COLLAGEN TYPE IV THAT HAS BEEN IMPLICATED IN THE ABILITY OF MALIGNANT TUMOR CELLS TO METASTASIZE AND IN THE PROCESS OF ANGIOGENESIS. A NATURALLY OCCURRING INHIBITOR OF THE 72 KD ENZYME KNOWN AS TIMP-2 (TISSUE INHIBITOR OF METALLOPROTEASE-2) FORM A NONCOVALENT COMPLEX WITH THE 72 KD TYPE IV PROCOLLAGENASE AND SPECIFICALLY INHIBITS ITS ENZYME ACTIVITY. THUS, TIMP-2 IS A POTENTIAL CANDIDATE FOR THE DEVELOPMENT OF NEW STRATEGIES FOR THE TREATMENT OF METASTASIS AND ANGIOGENIC DISEASES. WE INTEND TO PRODUCE MILLIGRAM QUANTITIES OF BIOLOGICALLY ACTIVE TIMP-2 AND 72 KD TYPE IV COLLAGENASE BY RECOMBINANT DNA TECHNOLOGY AND CHARACTERIZE THEIR BIOCHEMICAL AND BIOLOGICAL PROPERTIES. AVAILABILITY OF THESE PROTEINS WILL ALLOW US TO STUDY THEIR ROLE IN DISEASE AND TO DEVELOP ANTIBODIES AND SPECIFIC DRUGS TO BE USED IN IMMUNODIAGNOSTIC AND TREATMENT OF CANCER.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government